SWITCH Biotech

SWITCH Biotech AG was a German biopharmaceutical company focused on the development of novel therapeutics for dermatological conditions. Based in Martinsried, the company leveraged a proprietary functional genomics platform to identify and validate targets specifically related to skin diseases like psoriasis and chronic wounds. Their lead candidate, SB273, was a small molecule developed for the topical treatment of psoriasis. The company's research approach aimed to address the underlying molecular mechanisms of skin pathology rather than just treating symptoms. In November 2011, the company was acquired by LEO Pharma, a global leader in medical dermatology, allowing for the integration of SWITCH's innovative pipeline into LEO's global operations.